Join us Thursday, February 20th at 7 pm ET/4 pm PT for updates to our CCM Clinical Consensus Guidelines and a discussion of the Atorvastatin study results with Dr. Issam…
CCM 101 is an informational meeting for new members offered on the first Thursday of the month, at 7:00 PM Eastern. We’ll review slides covering the basics of the illness…
Recursion’s SYCAMORE trial meets primary endpoint of safety and demonstrates encouraging trends in objective MRI-based exploratory efficacy measures SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading…
Your generosity has made a difference! Get the full 2023 Impact Report here
We are thrilled to announce that the Phase 2 safety trial of Recursion’s REC-994 medicine, being developed specifically for symptomatic CCM, has fully enrolled 60 patients ahead of schedule. Our…
